Zolmitriptan:a new acute treatment for migraine

Bibliography

• HEADACHE CLASSIFICATION COMMITTEE OF THE IN-TERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgia's and facial pain. Cephalalgia (1988) 8\(Suppl. 7):1–6.
   Google Scholar
• LIPTON RB, SILBERSTEIN SD, STEWART WF: An update on the epidemiology of migraine. Headache (1994) 34:319–328.
   PubMed Web of Science ®Google Scholar
• STEWART WF, LIPTON RB: Societal impact of headache. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds.), Raven Press, New York, USA (1993):29–34.
   Google Scholar
• ISLER H: Historical background. In: The Headaches. Ole-sen J, Tfelt-Hansen P, Welch KMA (Eds.), Raven Press, New York, USA (1993):1–8.
   Google Scholar
• WOLFF HG: Headache and Other Head Pain. Oxford Uni-versity Press, New York (1948).
   Google Scholar
• SICUTERI F, TESTI A, ANSELMI B: Biochemical investiga-tions in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int. Arch. Allerg. (1961) 19:55–58.
   Google Scholar
• KIMBALL RW, FRIEDMAN AP, VALLEJO E: Effect of sero-tonin in migraine patients. Neurology (1960) 10:107–111.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, APPERLEY E, FENIUK W, PERREN MJ: Arational approach to identifying a fundamentally new drug for the treatment of migraine. In: Cardiovascular Pharmacology of 5-Hydroxyttyptamine: Prospective Thera-peutic Applications. Saxena PR, Wallis DI, Wouters W, Bevan P (Eds.), Kluwer Academic Publications, Dordrecht (1990416–431.
   Google Scholar
• PILGRIM AJ, BLAKEBOROUGH P: The clinical efficacy ofsumatriptan in the acute treatment of migraine. Rev. Contemp. Pharmacother. (1994) 5:295–309.
   Google Scholar
• VISSER WH, DE VRIEND RHM, JASPERS NWMH, FERRARI MD: Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology (1996) 47:46–51.
   PubMed Web of Science ®Google Scholar
• LEAO AAP: Spreading depression of activity in cerebral cortex. J. Neurophysiol. (1944) 7:359–390.
   Google Scholar
• LAURITZEN M: Cerebral blood flow in migraine and spreading depression. Acta Neurol. Scand. (1987) 76\(Suppl. 113):1–40.
   Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mecha-nisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol ScL (1992) 13:307–311.
   PubMed Web of Science ®Google Scholar
• HUSSEY EK, DONN KH, BUSCH MA, FOX AW, POWELL JR:Pharmacokinetics (PK) of oral sumatriptan in mi-graine patients during an attack and while painfree. Clin. Pharmacol. Ther. (1991) 49:134.
   Web of Science ®Google Scholar
• FOWLER PA, LACEY LF, THOMAS M et al.: The clinicalpharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. (1991) 31:291–294.
   PubMed Web of Science ®Google Scholar
• BATES D, ASHFORD E, DAWSON R et al.: Subcutaneoussumatriptan during the migraine aura. Neurology(1994) 44:1587–1592.
   PubMed Web of Science ®Google Scholar
• DAHLOF C: Would any acute treatment for migrainedemonstrate recurrence? Cephalalgia (1997) Suppl. 17:17–20.
   Google Scholar
• MACINTYRE P, GEMMILL J, HOGG K, BHARGAVA B: Theeffect of subcutaneous sumatriptan (GR43175) on cen-tral haemodynamics and the coronary circulation. Clin. Pharmacol. Ther. (1992) 51:152.
   Web of Science ®Google Scholar
• HUMPHREY PPA, FENIUK W, PERREN MJ, CONNOR HE,OXFORD AW: The pharmacology of the novel 5-HTi-like receptor agonist, GR43175. Cephalalgia (1989) 9\(Suppl. 9):23–33.
   Google Scholar
• FENIUK W, HUMPHREY PPA, PERREN MJ: GR43175 doesnot share the complex pharmacology of the ergots. Cephalalgia (1998) 9\(Suppl. 9):35–39.
   Google Scholar
• HUMPHREY PPA, FENIUK W, PERREN MJ: 5-HT in mi-graine: evidence from 5-HTi-like receptor agonists for a vascular aetiology. In: Migraine: A Spectrum of Ideas. Sandler M, Collins GM (Eds.), Oxford University Press, Ox-ford, UK (1990147–172.
   Google Scholar
• DOENICKE A, BRAND J, PERRIN VL: Possible benefit ofGR43175, a novel 5-HTi-like receptor agonist, for the acute treatment of severe migraine. Lancet (1988) 1(85901309–1311.
   Google Scholar
• DOENICKE A, MELCHART D, BAYLISS EM: Effective im-provement of symptoms in patients with acute mi-graine by GR43175 administered in dispersible tablets. Cephalalgia (1989) 9\(Suppl. 9):89–92.
   Google Scholar
• BRION N, BONS J, PLAS J, BAYLISS EM, ADVENIER C: Ini-tial clinical experience with the use of subcutaneous GR43175 in treating acute migraine. Cephalalgia (1989) 9\(Suppl. 9):79–82.
   Google Scholar
• PARSONS AA, WHALLEY ET: Evidence for the presence of 5-HTi-like receptors in rabbit isolated basilar arter-ies. Eur.J. Pharmacol (1989) 174:189–196.
   PubMed Web of Science ®Google Scholar
• PARSONS AA, WHALLEY ET, FENIUK W, CONNOR HE,HUMPHREY PPA: 5-HTt-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br. J. Pharmacol (1989) 96:434–440.
   PubMed Web of Science ®Google Scholar
• CONNOR HE, FENIUK W, HUMPHREY PPA: Characteriza-tion of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selec-tive 5-HTi-like receptor agonist. Br. J. Pharmacol (1989) 96:379–387.
   PubMed Web of Science ®Google Scholar
• FENIUK W, HUMPHREY PPA, PERREN MJ: The selective carotid arterial vasoconstrictor action of GR43175 in anaesthesized dogs. Br. J. Pharmacol (1989) 96:83–90.
   PubMed Web of Science ®Google Scholar
• PERREN MJ, FENIUK W, HUMPHREY PPA: The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia (1989) 9\(Suppl. 9):41–46.
   Google Scholar
• FRIBERG L: Effects of a new 5-HT1 -like receptor agonist, GR43175, on the regional brain tissue perfusion and intracerebral artery tone regulation in healthy volun-teers. Cephalalgia (1989) 9\(Supp1.10):359–360.
   Google Scholar
• BUZZI MG, MOSKOWITZ MA: The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura ma-ter. Br. J. Pharmacol. (1990) 99:202–206.
   PubMed Web of Science ®Google Scholar
• BUZZI MG, MOSKOWITZ MA: GR43175, a 5-HT1-like ago-nist, blocks neurogenic plasma protein extravasation in dura mater. Cephalalgia (1989) 9\(Suppl. 1027–28.
   Google Scholar
• HUMPHREY PPA, FENIUK W, MARRIOTT AS et al.: Pre-clinical studies on the anti-migraine drug, sumatrip-tan. Eur. Neurol (1991) 31:282–290.
   PubMedGoogle Scholar
• MARTIN GR: Preclinical pharmacology of zolmitriptan (Zomie; formerly 311c90), a centrally and peripher-ally acting 5-HT1st1n agonist for migraine. Cephalalgia (1997) 17 (Suppl. 17):4–14.
   Google Scholar
• GLEN RC, MARTIN GR, HILL AP, et al.: Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine proper-ties. J. Med. Chem. (1995) 38:3566–3580.
   Google Scholar
• MARTIN GR, ROBERTSON AD, MACLENNAN SJ et al. Re- ceptor specificity and trigemino-vascular inhibitory © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4) actions of a novel 5-HTI.B/1D partial agonist, 311C90 (zolmitriptan). Br. J. Pharmacol. (1997) 121:157–164.
   Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, COOK DA, HILL RG, HARGREAVES RJ: Preclinical comparative studies on the sympatholytic effects of 5-HT1D receptor agonists in vivo. In: Headache Treatment: Trial Methodology and New Drugs. Olesen J, Tfelt-Hansen P (Eds.), Lippincott-Raven, USA (1997):293–302.
   Google Scholar
• JONES JFX, MARTIN GR, RAMAGE A: Evidence that 5-HT1D receptors mediate inhibition of sympathetic ganglionic transmission in anaesthetised cats. Br. J. Pharmacol. (1995) 116:1715–1717.
   PubMed Web of Science ®Google Scholar
• DEN BOER MO, VILLALON CM, HEILIGERS JPC, HUM-PHREY PPA, SAXENA PR: Role of 5-HTi-like receptors in the reduction of porcine cranial arteriovenous anasto-motic shunting by sumatriptan. Br. J. Pharmacol. (1991) 102:323–330.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, DUCKWORTH JW: The effect of stimula-tion of the trigeminal ganglion on regional cerebral blood flow in the cat. Am. J. Physiol (1987) 253:R270–R274.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Peripheral and central tri-geminovascular activation in cat is blocked by the se-rotonin (511T)-1D receptor agonist 311C90. Headache (1994) 34:394–399.
   PubMed Web of Science ®Google Scholar
• SAITO K, MARKOWITZ S, MOSKOWITZ MA: Ergot alka-loids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann. Neurol (1988) 24:732–737.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, GOADSBY PJ: Controversies in head-ache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14:401–410.
   PubMed Web of Science ®Google Scholar
• HOSKIN KL, KAUBE H, GOADSBY PJ: Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain (1996) 119:1419–1428.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Vasoactive pep-tide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol (1990) 28:183–187.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Release of va-soactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovas-cular system. Ann. Neurol. (1988) 23:193–196.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: The trigeminovascular sys-tem and migraine: studies characterising cerebrovas-cular and neuropeptide changes seen in humans and cats. Ann. Neurol. (1993) 33:48–56.
   PubMed Web of Science ®Google Scholar
• MILLS A, RHODES P, MARTIN GR: [311]311C90 binding sites in cat brain stem: implications for migraine treat-ment. Cephalalgia (1995) 15 (Suppl. 14):116.
   Google Scholar
• GOADSBY PJ, KNIGHT YE: Direct evidence for central sites of action of zolmitriptan (311C90): an autoradio-graphic study in cat. Cephalalgia (1997) 17:153–158.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, HOSKIN KL: Inhibition of trigeminal neu-rons by intravenous administration of the serotonin (511T)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain (1996) 67(2-3):355–359.
   PubMed Web of Science ®Google Scholar
• KAUBE H, HOSKIN KL, GOADSBY PJ: Inhibition by su-matriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. (1993) 109:788–792.
   PubMed Web of Science ®Google Scholar
• SEABER E, ON N, DIXON RM et al.: The absolute bioavail-ability and metabolic disposition of the novel antimi-graine compound zolmitriptan (311C90). Br. J. Clin. Pharmacol. (1997) 43:579–587.
   PubMed Web of Science ®Google Scholar
• SEABER E, ON N, PHILLIPS S et al.: The tolerability andpharmacokinetics of the novel antimigraine com-pound 311C90 in healthy male volunteers. Br. J. Clin. Pharmacol. (1996) 41:141–147.
   PubMed Web of Science ®Google Scholar
• DIXON R: The pharmacokinetics and effect of food onthe absorption of 311C90 (Zomig) in healthy volun-teers. Eur. Neurol. (1997) 4\(Suppl. 0:63. Abstract P100.
   Google Scholar
• MARTIN GR: Preclinical and clinical pharmacology ofthe novel antimigraine compound 311C90. Headache (1995) 35:291. Abstract 17.
   Google Scholar
• ROLAN P: Potential drug interactions with the novelantimigraine compound zolmitriptan (Zomig®, 311C90). Cephalalgia (1997) 17 (Suppl. 18):21–27.
   Google Scholar
• DIXON RM, GILLOTIN C, GIBBENS M, POSNER J, PECKRW: The pharmacokinetics and effects on blood pres-sure of multiple doses of the antimigraine drug zol-mitriptan (311C90) in healthy volunteers. Br. J. Clin. Pharmacol. (1997) 43:273–281.
   PubMed Web of Science ®Google Scholar
• DIXON RM, MEIRE HB, EVANS DH et al.: Peripheral vas-cular effects and pharmacokinetics of the antimi-graine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia (1997) 17:639–646.
   PubMed Web of Science ®Google Scholar
• PRETTI-CECCHINI A, AFRA J, SCHOENEN J: Intensity de-pendence of the cortical auditory evoked potentials as a surrogate marker of CNS serotonin transmission in man: demonstration of a central effect for the 5HT1Bi1D agonist zolmitriptan (331c90, Zomig®). Cephalalgia (1997) 17:849–854.
   PubMed Web of Science ®Google Scholar
• SCHOENEN J: Measuring central action of acute antimi-graine drugs in man. Eur. Neurol (1997) 17 (Suppl. 17):12–16.
   Google Scholar
• MERCER AJ, SEABER E, LAMB RJ et al.: 311C90 has no clinically significant effect on psychometric task per-formance in healthy volunteers. Eur. J. Neurol. (1996) 3 (Suppl 5):151. Abstract 406.
   Google Scholar
• THOMSEN LL, DIXON R, LASSEN LH et al.: 311C90 (zol-mitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine - 1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia (1996) 16:270–275.
   PubMed Web of Science ®Google Scholar
• BOYLE R, BEHAN PO, SUTTON JA: A correlation be-tween severity of migraine and delayed gastric empty-ing measured by an epigastric impedance method. Br. Clin. Pharmacol. (1990) 30:405-409. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
   Google Scholar
• PECK RW, SEABER E, DIXON R et al: The pharmacody-namics and pharmacokinetics of the 5HT1B/1n agonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther. (In Press.)
   Google Scholar
• SMITH DA, PHILLIPS L, FLECK RJ et al.: 311C90 in nor-motensive and mild to moderate hypertensive volun-teers: a pharmacodynamic and pharmacokinetic comparison. Cephalalgia (1995) 15 (Suppl. 14)219. Ab-stract P17.
   Google Scholar
• GILLOTIN C, BAGNIS C, MAMET JP et al.: No need to ad-just the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Int. J. Clin. Pharmacol Ther. (1997) 35:522–526.
   PubMed Web of Science ®Google Scholar
• VERONESE L, GILLOTIN C, MARION- GALLOISR etal.: Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan. Clin. Drug Invest. (1997) 14:217–220.
   Google Scholar
• SEABER EJ, RIDOUT G, LAYTON G, POSNER J, PECK RW: The novel antimigraine compound zolmitriptan (`Zomig', 311C90) has no clinically significant interac-tions with paracetamol or metoclopramide. Eur. J. Clin. Pharmacol (1997) 53:229–234.
   PubMed Web of Science ®Google Scholar
• PECK RW, SEABER EJ, DIXON R et al.: The interaction be-tween propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol (1997) 44:595–599.
   PubMed Web of Science ®Google Scholar
• DIXON CM, PARK GR, TARBIT MH: Characterization ofthe enzyme responsible for the metabolism of suma-triptan in human liver. Biochem. Pharmacol (1994) 47:1253–1257.
   PubMed Web of Science ®Google Scholar
• SEABER EJ, GILLOTIN C, MOHANLAL R et al: Lack of in-teraction between pizotifen and the novel antimi-graine compound zolmitriptan in healthy volunteers. Clin. Drug Invest. (1997) 14:221–225.
   Web of Science ®Google Scholar
• SCHOENEN J, CAEKEBEKE P, LOUIS G et al.: An open study to investigate the absorption and tolerability of oral 311C90 in migraine patients. In: Proceedings of the 10th Migraine Trust Symposium, New Advances in Head-ache Research 4. Rose FC (Ed.), Smith-Gordon, London (1994):11–12.
   Google Scholar
• VISSER WH, KLEIN K, COX RC, JONES D, FERRARI M: 311C90, a new central and peripherally acting 5HT1n receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology (1996) 46:552–556.
   PubMedGoogle Scholar
• DAHLOF C, DIENER HC, GOADSBY P et al: A multicen-ter, double-blind, placebo-controlled dose-range find-ing study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache (1995) 35:292.
   Google Scholar
• SOLOMON GD, CADY RK, KLAPPER JA et al: The clinicalefficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49:1219–1225.
   Google Scholar
• RAPOPORT AM, RAMADAN NM, ADELMAN JU et al. Opti- mizing the dose of zolmitriptan (`Zomig', 311C90) for the acute treatment of migraine. Neurology (1997) 49:1210–1218.
   PubMed Web of Science ®Google Scholar
• DIENER HC, KLEIN K FOR THE MULTINATIONAL ORAL311C90 AND SUMATRIPTAN COMPARATIVE STUDY GROUP: The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of mi-graine. FuncI Neurol (1996) 11:152.
   Google Scholar
• BROWN DL, SWEET RM, FLETCHER P: 311C90 is effectivein patients who respond poorly to existing antimi-graine therapies. Eur. j Neurol (1996) 3 (Suppl. 5):152. Abstract P408.
   Google Scholar
• BATES D, ASHFORD E, DAWSON R et al.: Subcutaneoussumatriptan during the migraine aura. Neurology (1994) 44:1587–1592.
   PubMed Web of Science ®Google Scholar
• DOWSON A: Can oral 311C90, a novel 5HT1u agonist,prevent migraine headache when taken during an aura? Eur. Neurol. (1996) 36\(Suppl. 2):28–31.
   Google Scholar
• ZAGAMI AS FOR THE INTERNATIONAL 311C90 LONG-TERM STUDY GROUP: 311C90: long term efficacy and tolerability profile for the acute treatment of migraine. Neurology (1997) 48 (Suppl. 3):525–S28.
   Google Scholar
• LIPTON RB, STEWART WF: Clinical applications of zol-mitriptan (ZomigTh`, 311C90). Cephalalgia (1997) 17 (Suppl. 18):53–59.
   Google Scholar
• SCHOENEN J, SAWYER J: Zolmitriptan (ZomigTm, 311C90), a novel dual central and peripheral 5HT1B/1n agonist: an overview of efficacy. Cephalalgia (1997) 17 (Suppl 18):28–40.
   PubMedGoogle Scholar
• HAMALAINEN ML, HOPPU K, SANTAVUORI P: Sumatrip-tan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology (1997) 48:1100–1109.
   Google Scholar
• SOLBACH P, SARGENT J, COYNE L: Menstrual migraine headache: results of a controlled experimental out-come study of non-drug treatments. Headache (1984) 24:75–78.
   PubMed Web of Science ®Google Scholar
• LODER E, SOLOMON G, SILBERSTEIN S: Clinical re-sponse to zolmitriptan (`Zomig) in three migraine subtypes: migraine associated with menses, with aura, and well-developed migraine. Headache (1997) 37:321.
   Google Scholar
• Data on file. Zeneca.
   Google Scholar
• SWEET RM, BROWN DL, WALKER A: The high efficacy of311C90 in treating migraine is maintained in patients using oral contraceptives. Cephalalgia (1996) 16:396. Abstract 103.
   Google Scholar
• EDMEADS JG, MILLSON DS: Tolerability profile of zol-mitriptan (Zomir; 311C90), a novel dual central and peripherally acting 5HT1si1D agonist. International clinical experience based on 3000 subjects treated with zolmitriptan. Cephalalgia (1997) 17 (Suppl. 18)41–52.
   Google Scholar
• VISSER WH, TERWINDT GM, REINES SA et al.: Rizatriptanvs. sumatriptan in the acute treatment of migraine. Arch. Neurol. (1996) 53:1132–1137.
   PubMed Web of Science ®Google Scholar
• TEPPER SJ. `Zomig' in clinical practice. Extended abstract from Zeneca sponsored symposium at the World Congress of Neurology. Buenos Aires (1997).
   Google Scholar
• MCKENNA S, PATRICK D: Development of a migraine specific quality of life measure for multinational clini-cal trials. Cephalalgia (1995) 15 (Suppl. 14):280.
   Google Scholar
• MATHEW N, SHEFTELL F, SILBERSTEIN S, WINNER P, PAT-RICK P: Evaluation of the improvement in migraine-
   Google Scholar